Tessera Therapeutics Overview
Pro stress-test →Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing™, a new approach to genome engineering that is designed to write therapeutic messages into the genome to treat diseases at their source. The company was founded in 2018 by Flagship Pioneering, a top-tier biotech venture firm. Tessera represents a new category of genetic medicine that aims to unlock curative therapies for monogenic disorders, common diseases, and oncology indications.
Strategic Profile
Pro stress-test →Tessera's Gene Writing platform is designed to write therapeutic messages into the genome by efficiently changing single or multiple DNA base pairs, precisely correcting insertions and deletions, or adding exon-length sequences and whole genes, leveraging a proprietary lipid nanoparticle delivery platform designed to enable the in vivo delivery of RNA to targeted cell types. The company's lead program, TSRA-196, received FDA Fast Track and Orphan Drug designations in February 2026 and is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD).
Competitive Landscape
Pro stress-test →Tessera competes in the broader genetic medicine space against established CRISPR gene editing platforms (CRISPR Therapeutics, Editas Medicine), gene therapy companies (Sesen Bio, Bluebird Bio, Sangamo), and emerging in vivo gene editing platforms. Key differentiator is the Gene Writing approach, which writes therapeutic sequences into the genome rather than cutting DNA, potentially offering advantages in precision and durability. Flagship Pioneering's portfolio companies like Moderna and Denali Therapeutics represent allied but distinct approaches.
Industry Context
Tessera Therapeutics operates in Gene writing and genome engineering therapeutics.
Key facts
Founded: 2018 · Headquarters: Cambridge, US · Employees: 201-500